Halter Ferguson Financial Inc. Acquires 376,795 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL)

Halter Ferguson Financial Inc. raised its holdings in Candel Therapeutics, Inc. (NASDAQ:CADL) by 123.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 681,334 shares of the company’s stock after purchasing an additional 376,795 shares during the period. Candel Therapeutics comprises 2.4% of Halter Ferguson Financial Inc.’s holdings, making the stock its 6th largest position. Halter Ferguson Financial Inc.’s holdings in Candel Therapeutics were worth $5,914,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of CADL. Rhumbline Advisers boosted its stake in shares of Candel Therapeutics by 17.0% in the fourth quarter. Rhumbline Advisers now owns 26,272 shares of the company’s stock worth $228,000 after acquiring an additional 3,817 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new stake in shares of Candel Therapeutics in the fourth quarter worth approximately $329,000. FMR LLC acquired a new stake in shares of Candel Therapeutics in the third quarter worth approximately $46,000. Geode Capital Management LLC boosted its stake in shares of Candel Therapeutics by 12.8% in the third quarter. Geode Capital Management LLC now owns 448,997 shares of the company’s stock worth $3,112,000 after acquiring an additional 51,111 shares during the last quarter. Finally, Barclays PLC boosted its stake in shares of Candel Therapeutics by 327.1% in the third quarter. Barclays PLC now owns 28,688 shares of the company’s stock worth $199,000 after acquiring an additional 21,971 shares during the last quarter. 13.93% of the stock is owned by institutional investors and hedge funds.

Candel Therapeutics Stock Up 0.9 %

NASDAQ:CADL opened at $8.83 on Tuesday. Candel Therapeutics, Inc. has a 52 week low of $1.34 and a 52 week high of $14.60. The company has a market capitalization of $286.76 million, a P/E ratio of -5.10 and a beta of -1.29. The stock’s fifty day moving average is $8.22 and its two-hundred day moving average is $6.97.

Candel Therapeutics (NASDAQ:CADL) last posted its earnings results on Thursday, March 13th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.17). Sell-side analysts anticipate that Candel Therapeutics, Inc. will post -1.47 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on CADL shares. Canaccord Genuity Group lifted their price target on Candel Therapeutics from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, February 26th. HC Wainwright reiterated a “buy” rating and set a $19.00 price objective on shares of Candel Therapeutics in a research report on Friday. Bank of America started coverage on Candel Therapeutics in a research report on Friday, February 7th. They set a “buy” rating and a $15.00 price objective on the stock. Finally, Citigroup started coverage on Candel Therapeutics in a research report on Thursday, February 20th. They set a “buy” rating and a $25.00 price objective on the stock.

Insider Buying and Selling at Candel Therapeutics

In related news, CTO Seshu Tyagarajan sold 14,322 shares of the business’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $7.22, for a total value of $103,404.84. Following the sale, the chief technology officer now owns 96,790 shares in the company, valued at approximately $698,823.80. The trade was a 12.89 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Francesca Barone sold 13,673 shares of the business’s stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $8.22, for a total value of $112,392.06. Following the completion of the sale, the insider now owns 124,207 shares in the company, valued at $1,020,981.54. This represents a 9.92 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 41,529 shares of company stock worth $313,512 over the last quarter. 41.60% of the stock is currently owned by company insiders.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.